TNF-alpha, IL-8, IL-6 levels in serum of sarcoidosis patients with different clinical course Source: Annual Congress 2013 –Sarcoidosis and other granulomatosis Year: 2013
The evaluation of serum biomarkers in patients with sarcoidosis: Can visfatin be a new biomarker for sarcoidosis? Source: International Congress 2017 – Rare diseases Year: 2017
Serum IL-17 and IL-18 levels in asthma-COPD overlap syndrome patients Source: International Congress 2015 – Promising novel findings in translational pulmonary research Year: 2015
Elevated serum inflammatory markers in patients with stable COPD Source: Annual Congress 2009 - Respiratory mechanics, tissue and cell dysfunction in pulmonary disease Year: 2009
YKL-40, soluble IL-2 receptor, ADA and neopterin: comparison of markers of sarcoidosis activity Source: Annual Congress 2009 - Sarcoidosis in review Year: 2009
Serum C-reactive protein concentrations in patients with sarcoidosis: can be taken this simple test as an activation marker in sarcoidosis? Source: Eur Respir J 2004; 24: Suppl. 48, 712s Year: 2004
Multiplex immune serum biomarker profiling in sarcoidosis and systemic sclerosis Source: Eur Respir J 2009; 34: 1376-1382 Year: 2009
Serum markers of acute sarcoidosis. Source: Virtual Congress 2020 – Genetics and biomarkers for diagnosis and prognosis of granulomatous lung diseases Year: 2020
TNF-a and IL-10 control macrophage expression of CXCL13, a prognostic biomarker of idiopathic pulmonary fibrosis Source: International Congress 2018 – Back to basics and translational research in idiopathic interstitial pneumonias Year: 2018
Serum neopterin and IL-6 as biomarkers in patients with COPD. Source: International Congress 2017 – Novel molecular and genetic targets in COPD Year: 2017
The serum levels of endothelin (ET-1); an activation marker and prognostic indicator in sarcoidosis? Source: Eur Respir J 2005; 26: Suppl. 49, 80s Year: 2005
Elevated serum LOXL2 levels are associated with rapid disease progression in idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012
Increased CCL18 serum levels in patients with pulmonary fibrosis which reflect disease severity Source: Eur Respir J 2005; 26: Suppl. 49, 21s Year: 2005
Serum biomarkers in SSc-ILD: association with presence, severity and prognosis Source: International Congress 2019 – From biomarkers to treatment of immune-mediated interstitial lung disease: what’s new? Year: 2019
Serum TNFα and IL8 as markers of systemic inflammation in severe asthma Source: Eur Respir J 2005; 26: Suppl. 49, 279s Year: 2005
Serum KL-6 as a marker of disease progression in SSc-ILD Source: International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: from the bench to the bedside Year: 2018
Evaluation of CCL18 serum levels and genetic variant as prognostic biomarkers in SSc-ILD Source: Virtual Congress 2021 – Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases Year: 2021
Elevated serum IL-8: a biomarker indicating exacerbation-prone COPD Source: International Congress 2017 – COPD biomarkers Year: 2017
The relationship between serum soluble interleukin-2 receptor levels and disease severity in sarcoidosis Source: Eur Respir J 2006; 28: Suppl. 50, 355s Year: 2006
Levels of IGFBP-1, MMP-9 and circulating nucleosomes: a new model to diagnose SSc-ILD Source: Virtual Congress 2020 – Predictive markers of progression in connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis Year: 2020